

Danny L. Williams
Terry D. Morgan
J. Mike Amerson
Kenneth D. Goodman
Jeffrey A. Pyle
Jaison C. John
Bradley A. Misley
Ruben S. Bains

WILLIAMS, MORGAN & AMERSON, P.C.

7676 HILLMONT, SUITE 250, HOUSTON, TX 77040 (713) 934-7000 Fax (713) 934-7011

Scott F. Diring*

George J. Oehling*

Shelley P.M. Fussey, Ph.D.*

Mark D. Moore, Ph.D.*

Louis H. Iselin, Ph.D.*

Raymund F. Eich, Ph.D.*

Thomas H. Belvin, Jr.*

Daren C. Davis*

Stephanie A. Wardwell, Ph.D.*

*Patent Agent

WRITER'S DIRECT DIAL: (713) 934-4079

November 27, 2001

File: 4001.002282

CERTIFICATE OF MAILING 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date below:

November 27, 2001

Date

Shelley P.M. Fussey

Assistant Commissioner for Patents Washington, DC 20231

RE: U.S. Application Serial No. 09/351,862; Entitled "Cancer Treatment Kits Using Antibodies to Aminophospholipids"; By Thorpe and Ran; Client Ref.: UTSMC/DAL:549--1

Sir:

Enclosed for filing in the above-referenced patent application is:

- (1) Supplemental Information Disclosure Statement, PTO Form 1449 and copies of References A22 and C52-C54;
- Original signed version of Declaration of Philip E. Thorpe and Sophia Ran Under 37 C.F.R. § 1.131; and
- (3) A postcard listing these materials; please date stamp and return the postcard evidencing receipt of these materials.

WILLIAMS, MORGAN & AMERSON, P.C.

Assistant Commissioner for Patents November 27, 2001 Page 2

The original, signed document is to supplement the version with the facsimile signatures first submitted on September 21, 2001. The current document is the same as the one already on file except for the original signatures.

No fees are believed to be due relating to the enclosed; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary, the Assistant Commissioner is hereby authorized to deduct said fees from Williams, Morgan & Amerson, P.C. Deposit Account No. 50-0786/4001.002282.

Respectfully submitted,

Shelley P.M. Fussey, Ph.D.

Reg. No. 39,458 Patent Agent

Encls.



CERTIFICATE OF MAILING 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date below:

November 27, 2001

Date

Shelley P.M. Fussey

FOR S 2022

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Philip E. Thorpe and Sophia Ran

Serial No.: 09/351,862

Filed: July 12, 1999

For: CANCER TREATMENT KITS USING

ANTIBODIES TO

AMINOPHOSPHOLIPIDS

Group Art Unit: 1619

Examiner: Sharareh, S.

Atty. Dkt. No.: 4001.002282

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record in the present case. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A first Official Action reflecting examination on the merits has been received in the present application. However, this Supplemental Information Disclosure Statement is being filed prior to the mailing of a final Official Action, notice of allowance or an Action that closes prosecution, and is timely filed in accordance with 37 C.F.R. § 1.97(c) without a fee in light of the following information.

Applicants first certify, in accordance with 37 C.F.R. § 1.97(e)(1), that the three listed scientific references were each cited in a communication from a foreign patent office in a related foreign application not more than three months prior to the filing of the present statement. Specifically, the three scientific references were cited in a communication mailed from the European Patent Office on October 23, 2001. In any event, these three references are believed to be cumulative over prior art already of record.

ì,

The listed U.S. patent was not cited in a communication from a foreign patent office in a counterpart foreign application, but only issued on November 06, 2001, and could not have been known to the applicants prior to that date. The application from which the patent issued has already been disclosed to the Office, the patent is cumulative over co-pending applications already of record, and issued from a co-pending application that has the same effective filing date as the present case, and so cannot be considered as "prior".

No fees should be due in connection with the filing of this Supplemental Information Disclosure Statement. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary, the Examiner should contact the undersigned representative to discuss deduction from Williams, Morgan & Amerson Deposit Account No. 50-0786/4001.002282.

Respectfully submitted,

Shelley P.M. Fussey Reg. No. 39,458

Agent for Applicants

WILLIAMS, MORGAN & AMERSON, P.C. 7676 Hillmont, Suite 250 Houston, Texas, 77040 (713) 934-4079

Date: November 27, 2001